Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Accounts Payables (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Accounts Payables for 14 consecutive years, with $45631.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 12.23% year-over-year to $45631.0, compared with a TTM value of $45631.0 through Nov 2025, down 12.23%, and an annual FY2025 reading of $49252.0, up 20.59% over the prior year.
  • Accounts Payables was $45631.0 for Q4 2025 at CNBX Pharmaceuticals, down from $49252.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.0 million in Q2 2023 and bottomed at $40841.0 in Q3 2024.
  • Average Accounts Payables over 5 years is $233734.8, with a median of $212047.0 recorded in 2021.
  • The sharpest move saw Accounts Payables soared 353.95% in 2023, then plummeted 87.84% in 2024.
  • Year by year, Accounts Payables stood at $200449.0 in 2021, then rose by 11.57% to $223645.0 in 2022, then increased by 9.87% to $245712.0 in 2023, then tumbled by 78.84% to $51992.0 in 2024, then decreased by 12.23% to $45631.0 in 2025.
  • Business Quant data shows Accounts Payables for CNBX at $45631.0 in Q4 2025, $49252.0 in Q3 2025, and $41239.0 in Q2 2025.